Nicotine and Autism: Dr. Ardis on the Nicotinic Receptor in Autism

Table of Contents

1. What Dr. Ardis Says
2. A Plain Primer: The Nicotinic Receptor
3. Nicotinic Receptors in Autism Brain Tissue
4. The CHRNA7 Gene and the 15q13.3 Deletion
5. The Yale Trial of a Nicotine Patch in Adults With Autism
6. Galantamine Trials in Autism
7. Drugs Aimed at the α7 and α4β2 Receptors
8. Nicotine in a Mouse Model of Autism
9. Safety Notes
10. Dr. Ardis’s Own Work
11. Key Research Papers
12. Connections
13. Featured Videos

1. What Dr. Ardis Says

Dr. Ardis set this out in a 2025 podcast appearance (Culture Apothecary) and in his book Moving Beyond the COVID-19 Lies: Restoring Health and Hope for Humanity.

The autism statement comes straight after his account of how the research studies use nicotine. He states that every research study on the diseases he had just listed uses 7 mg nicotine patches, one new patch daily, for seven days. He then turns to autism:

“Nicotine’s also proven to help reverse and improve all personality traits and actions of autistic children.”

When autism is raised, he adds “and adults,” and gives the method: a 7 mg nicotine patch placed between the shoulder blades. That 7 mg figure is the adult dose. This site prints no milligram amount for a child. The site’s Nicotine Patch Protocol page sets out his step-up scheme for adults.

In the same passage he describes his general titration for adults who are new to nicotine: begin with about 1 mg (biting a 2 mg gum in half, or cutting a patch into small pieces) for a week, step up to about 3½ mg for a few weeks, and then go up to 7 mg.

His wider framework is set out on the Nicotine Hypothesis page: that nicotine occupies and protects the nicotinic acetylcholine receptor, and that conditions involving that receptor respond to it. Autism is one of the conditions he places in that list.

Back to Table of Contents

2. A Plain Primer: The Nicotinic Receptor

Acetylcholine is one of the brain’s chemical messengers. One family of its receptors is called nicotinic because nicotine fits the same lock. Each receptor is a ring of five protein pieces (subunits) around a channel; when acetylcholine or nicotine binds, the channel opens and lets charged particles into the nerve cell.

Two kinds matter most for autism research:

• α4β2 — the most common nicotinic receptor in the brain, and the one nicotine binds most tightly. It is involved in attention and in the brain’s reward signalling.
• α7 — made of five identical α7 pieces, built from the CHRNA7 gene. It is involved in filtering incoming sensory information, in memory, and in calming inflammation.

Researchers measure these receptors in brain tissue by how much of a tagged chemical sticks to them: epibatidine binding mainly reflects α4β2-type receptors, and α-bungarotoxin binding (a toxin from a krait snake) reflects α7. The site’s Nicotinic Acetylcholine Receptors page covers the receptor family in more detail.

Back to Table of Contents

3. Nicotinic Receptors in Autism Brain Tissue

The starting point for the whole research area is a series of post-mortem studies from the Newcastle brain bank in the United Kingdom, led by Elaine Perry and colleagues, which compared donated brain tissue from autistic adults with tissue from adults without autism.

Cerebral cortex (Perry et al., 2001)

Writing in the American Journal of Psychiatry, the team measured the acetylcholine system in the frontal and parietal cortex. The enzymes that make and break down acetylcholine were normal. The striking difference was in nicotinic receptors: epibatidine binding was 65–73% lower in the autistic group than in normal controls, in both cortical areas, and the α4 and β2 subunits were lower in the parietal cortex. The lower epibatidine binding was also seen in a comparison group with intellectual disability but without autism. The authors concluded that the findings implicated the cholinergic system in autism and “suggest the potential for intervention based on cholinergic receptor modulation.”

Cerebellum (Lee et al., 2002)

In Brain, the same group studied the cerebellum of eight autistic individuals, ten controls and eleven non-autistic people with intellectual disability. Epibatidine binding (the α4-type receptor) was reduced by 40–50% in the autistic group. α-Bungarotoxin binding (α7) went the other way, about three times higher in one layer, which the authors read as a possible compensatory increase. They wrote that because nicotinic agonists improve attention and raise the high-affinity receptor, “nicotinic therapy in autism may be worth considering.”

Gene activity (Martin-Ruiz et al., 2004)

A follow-up measured the receptor genes’ messenger RNA alongside protein and binding. In the parietal cortex, α4 messenger RNA, α4 and β2 protein and receptor binding were all lower in autism, while α7 was unchanged there. In the cerebellum, α4 messenger RNA was higher but α4 protein and binding were lower, and α7 binding was higher. The authors concluded that reduced α4β2 gene expression in the cortex is “a major feature of the neurochemical pathology of autism.”

Back to Table of Contents

4. The CHRNA7 Gene and the 15q13.3 Deletion

The α7 receptor is built from the CHRNA7 gene, which sits in a stretch of chromosome 15 called 15q13.3. In some people a small piece of that stretch is missing (a microdeletion) or doubled (a duplication).

Miller and colleagues at Children’s Hospital Boston (Journal of Medical Genetics, 2009) examined DNA from 1,445 patients referred for genetic testing and 1,441 individuals with autism from the Autism Genetic Resource Exchange. They described five patients with the deletion and five with duplications. The deletion cases had language delays and a range of neuropsychiatric features including autism spectrum disorder, attention deficit hyperactivity disorder, anxiety and mood disorder. Both the deletion and duplication spanned CHRNA7.

Deutsch and colleagues (2016) reviewed the 15q13.3 deletion syndrome and argued that losing one copy of CHRNA7 reduces α7 signalling and that this may be one mechanism behind the neurodevelopmental disorders seen with it. A 2020 review by Deutsch and Burket set out the case for testing drugs that target the α7 receptor in autism, and a 2024 review by Oz and colleagues surveyed the same field with a focus on α7.

Back to Table of Contents

5. The Yale Trial of a Nicotine Patch in Adults With Autism

The study that matches Dr. Ardis’s method most closely is a small trial from the Yale School of Medicine, published by Lewis, van Schalkwyk, Lopez, Volkmar, Picciotto and Sukhodolsky in the Journal of Autism and Developmental Disorders in 2018.

• Who: adults with autism spectrum disorder who had aggression and irritability.
• Design: double-blind crossover — each person had one week of a 7 mg transdermal nicotine patch and one week of a placebo patch, in random order, without knowing which was which.
• Size: eight people were randomized; five contributed data to the main outcome.
• Main measure: the Irritability subscale of the Aberrant Behavior Checklist, a standard caregiver-rated scale.
• What they reported: all participants tolerated nicotine well; irritability improved on nicotine compared with placebo; sleep ratings also improved on nicotine and tracked the irritability improvement.

The authors described it as an exploratory trial testing feasibility and tolerability, and wrote that the findings “support further investigation” of nicotinic receptor agonists for aggression and sleep in autism. The dose (7 mg) and the length of each treatment period (one week) are the same as the figures Dr. Ardis gives.

Back to Table of Contents

6. Galantamine Trials in Autism

Galantamine is a medicine first isolated from snowdrop and daffodil-family plants. It works in two ways: it slows the breakdown of acetylcholine, and it makes nicotinic receptors respond more strongly to acetylcholine (an “allosteric potentiator”). It is used for Alzheimer’s disease, and researchers have tried it in autism because it strengthens the same receptor system.

Niederhofer, Staffen and Mair (2002)

An Austrian team published a short letter in the BMJ titled “Galantamine may be effective in treating autistic disorder,” reporting their early experience treating children with autism with galantamine and proposing it for further study.

Ghaleiha et al. (2014)

A randomized, double-blind, placebo-controlled trial from Tehran University of Medical Sciences, published in the Journal of Psychopharmacology. Forty children aged 4 to 12 with autism and marked irritability, all taking risperidone, were given either galantamine or placebo as an add-on for 10 weeks. By the end, the galantamine group had improved significantly more on the Irritability scale and on the Lethargy/Social Withdrawal scale than the placebo group, and side effects did not differ significantly between the groups. The authors called galantamine augmentation “a relatively effective and safe augmentative strategy” for some autism-related symptoms.

Back to Table of Contents

7. Drugs Aimed at the α7 and α4β2 Receptors

Because nicotine acts on many receptor types at once, researchers have also tried more selective drugs.

• An α7 partial agonist (Olincy et al., 2016). At the University of Colorado, two adults with autism took part in a double-blind, placebo-controlled crossover study of an investigational drug that stimulates the α7 receptor. A brain-wave test of sensory filtering (P50 inhibition) showed the intended effect, neuropsychological testing showed an effect on attention, and both patients rated their own attention as improved.
• Varenicline (Mostafavi, Hardy and Arnold, 2016). A case report from Ohio State University on a 19-year-old man with severe autism given low-dose varenicline, a stop-smoking medicine that partly stimulates α4β2 receptors. He improved clinically and several urine and saliva markers normalised; he worsened when it was stopped and improved again when it was restarted, and remained on it for over a year without noticeable side effects. The authors called for controlled research before clinical recommendations.

Back to Table of Contents

8. Nicotine in a Mouse Model of Autism

The BTBR mouse is a widely used laboratory strain that shows reduced social interest and repetitive behaviours, and is studied as a model of autism.

• Wang et al. (2015), Children’s National Health System, Washington DC. Mice drank water containing nicotine for four weeks at four strengths. At the lower strengths nicotine increased social interaction in both BTBR and ordinary mice; at the higher strengths it reduced repetitive behaviour in BTBR mice but also reduced overall activity, and the highest strength caused weight loss.
• Mahmood et al. (2020), King Saud University, Riyadh. Two weeks of oral nicotine improved sociability and reduced repetitive behaviour in BTBR mice, with no effect in ordinary mice. Mecamylamine, a drug that blocks nicotinic receptors, reversed nicotine’s effect on sociability — evidence that the effect ran through those receptors.

These are animal studies; they show what nicotine does to behaviour in a mouse strain, not in people.

Back to Table of Contents

9. Safety Notes

• Children and pets: nicotine is poisonous to small bodies. A used patch still holds a large share of its nicotine. Keep new and used patches, gum and lozenges out of reach of children and pets; fold used patches sticky-side together before discarding. If a child or pet chews or swallows one, call Poison Control (1-800-222-1222 in the United States) or a vet at once.
• No child doses are given on this site. Any use of nicotine in a child is a decision for a clinician who knows that child.
• Who should not use nicotine: pregnancy and breastfeeding, unstable heart disease or a recent heart attack, recent stroke, serious heart-rhythm problems, and uncontrolled high blood pressure. Nausea, dizziness, a racing heart and vivid dreams are signs of too much.
• The full list of contraindications is on the Nicotine Patch Protocol page.

Back to Table of Contents

10. Dr. Ardis’s Own Work

• Moving Beyond the COVID-19 Lies: Restoring Health and Hope for Humanity — the site’s page on his book.
• Dr. Bryan Ardis Hub — the wing’s main page, with his nicotine hypothesis and every page in the wing.

Back to Table of Contents

Key Research Papers

1. Lewis AS, van Schalkwyk GI, Lopez MO, Volkmar FR, Picciotto MR, Sukhodolsky DG (2018). An Exploratory Trial of Transdermal Nicotine for Aggression and Irritability in Adults with Autism Spectrum Disorder. J Autism Dev Disord. — PubMed PMID: 29536216
2. Perry EK, Lee ML, Martin-Ruiz CM, Court JA, et al. (2001). Cholinergic activity in autism: abnormalities in the cerebral cortex and basal forebrain. Am J Psychiatry. — PubMed PMID: 11431227
3. Lee M, Martin-Ruiz C, Graham A, Court J, et al. (2002). Nicotinic receptor abnormalities in the cerebellar cortex in autism. Brain. — PubMed PMID: 12076999
4. Martin-Ruiz CM, Lee M, Perry RH, Baumann M, Court JA, Perry EK (2004). Molecular analysis of nicotinic receptor expression in autism. Brain Res Mol Brain Res. — PubMed PMID: 15046869
5. Miller DT, Shen Y, Weiss LA, Korn J, et al. (2009). Microdeletion/duplication at 15q13.2q13.3 among individuals with features of autism and other neuropsychiatric disorders. J Med Genet. — PubMed PMID: 18805830
6. Deutsch SI, Burket JA, Benson AD, Urbano MR (2016). The 15q13.3 deletion syndrome: Deficient α7-containing nicotinic acetylcholine receptor-mediated neurotransmission in the pathogenesis of neurodevelopmental disorders. Prog Neuropsychopharmacol Biol Psychiatry. — PubMed PMID: 26257138
7. Deutsch SI, Burket JA (2020). An Evolving Therapeutic Rationale for Targeting the α7 Nicotinic Acetylcholine Receptor in Autism Spectrum Disorder. Curr Top Behav Neurosci. — PubMed PMID: 32468495
8. Oz M, Kury LA, Sadek B, Mahgoub MO, et al. (2024). The role of nicotinic acetylcholine receptors in the pathophysiology and pharmacotherapy of autism spectrum disorder: Focus on α7 nicotinic receptors. Int J Biochem Cell Biol. — PubMed PMID: 39094731
9. Niederhofer H, Staffen W, Mair A (2002). Galantamine may be effective in treating autistic disorder. BMJ. — PubMed PMID: 12480867
10. Ghaleiha A, Ghyasvand M, Mohammadi MR, Farokhnia M, et al. (2014). Galantamine efficacy and tolerability as an augmentative therapy in autistic children: A randomized, double-blind, placebo-controlled trial. J Psychopharmacol. — PubMed PMID: 24132248
11. Olincy A, Blakeley-Smith A, Johnson L, Kem WR, Freedman R (2016). Brief Report: Initial Trial of Alpha7-Nicotinic Receptor Stimulation in Two Adult Patients with Autism Spectrum Disorder. J Autism Dev Disord. — PubMed PMID: 27565651
12. Mostafavi M, Hardy P, Arnold LE (2016). Varenicline in Autism: Theory and Case Report of Clinical and Biochemical Changes. J Child Adolesc Psychopharmacol. — PubMed PMID: 27123827
13. Wang L, Almeida LE, Spornick NA, Kenyon N, et al. (2015). Modulation of social deficits and repetitive behaviors in a mouse model of autism: the role of the nicotinic cholinergic system. Psychopharmacology (Berl). — PubMed PMID: 26337613
14. Mahmood HM, Aldhalaan HM, Alshammari TK, Alqasem MA, et al. (2020). The Role of Nicotinic Receptors in the Attenuation of Autism-Related Behaviors in a Murine BTBR T + tf/J Autistic Model. Autism Res. — PubMed PMID: 32691528

PubMed Topic Searches

1. PubMed: Nicotinic receptors and autism
2. PubMed: CHRNA7 and autism
3. PubMed: Galantamine in autism
4. PubMed: Transdermal nicotine in autism

Back to Table of Contents

Connections

• Dr. Bryan Ardis Hub — the wing’s main page: his nicotine hypothesis and snake-venom theory
• The Nicotine Hypothesis — the receptor framework his autism statement rests on
• Nicotine Patch Protocol — his dosing, placement and the full contraindication list
• Nicotinic Acetylcholine Receptors — the receptor family in detail
• Dietary Nicotine and Parkinson’s — another condition in his nicotinic list
• Cobra Venom and Nicotine — his account of the receptor that venom and nicotine share
• Moving Beyond the COVID-19 Lies — his book
• Autism — the site’s main page on autism
• Autism Spectrum Disorder — the pediatric view
• Choline, Cognition and Acetylcholine — the nutrient the body makes acetylcholine from

Back to Table of Contents

Featured Videos